Our congratulations to Fisher Adams Kelly client Ellex on last month’s grant of CE mark approval for their new laser treatment for age-related macular degeneration (AMD). With this approval, the Australian company can now proceed to sell its new product in the EU, Australia and other markets around Asia and South America.
AMD is the leading cause of blindness in the developed world, and Ellex Medical’s treatment is the only one for the early stages of the disease with a CE mark in place. We understand that the next stage for this treatment will be its roll out in a number of key clinical sites in the European Union.
We take great pride from having been involved in the protection of this market-leading technology for a number of years, in Australia and around the world. We are grateful for the opportunities our clients provide to support them in these important ventures.
More details of Ellex Medical’s treatment can be found at their website, here.